The HIV-1 gag p6: a promising target for therapeutic intervention.

Antiretrovirals HIV-1 Gag p6 Viral replication and budding

Journal

Retrovirology

ISSN: 1742-4690

Titre abrégé: Retrovirology

Pays: England

ID NLM: 101216893

Informations de publication

Date de publication:
23 Jan 2024

Historique:

received: 20 11 2023

accepted: 12 01 2024

medline: 24 1 2024

pubmed: 24 1 2024

entrez: 23 1 2024

Statut: epublish

Résumé

The p6 domain of the Gag precursors (Gag p6) in human immunodeficiency virus type 1 (HIV-1) plays multifunctional roles in the viral life cycle. It utilizes the endosomal sorting complex required for transport (ESCRT) system to facilitate viral budding and release from the plasma membrane through the interactions with the ESCRT-I component tumor susceptibility gene 101 (TSG101) and with the ALG-2 interacting protein X (ALIX). Moreover, Gag p6 contributes to viral replication by a range of posttranslational modifications such as SUMOylation, ubiquitination and phosphorylation. Additionally, Gag p6 also mediates the incorporation of the accessory protein Vpr into virions, thereby promoting Vpr-induced viral replication. However, less attention is focused on Gag p6 as therapeutic intervention. This review focuses on the structures and diverse functions of Gag p6 in viral replication, host cells, and pathogenesis. Additionally, several challenges were also discussed in studying the structure of Gag p6 and its interactions with partners. Consequently, it concludes that the Gag p6 represents an attractive target for the development of antiretroviral drugs, and efforts to develop p6-targeted antiretrovirals are expected to undergo significant growth in the forthcoming years.

Identifiants

DOI: 10.1186/s12977-024-00633-2 PMID: 38263239

pubmed: 38263239

doi: 10.1186/s12977-024-00633-2

pii: 10.1186/s12977-024-00633-2

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Pagination

Subventions

Organisme : Binzhou Medical University

ID : No Number

Organisme : Binzhou Medical University

ID : No Number

Informations de copyright

Références

Freed EO. HIV-1 assembly, release and maturation. Nat Rev Microbiol. 2015;13:484–96. https://doi.org/10.1038/nrmicro3490 .

doi: 10.1038/nrmicro3490 pubmed: 26119571 pmcid: 6936268

Qu K, Ke Z, Zila V, Anders-Össwein M, Glass B, Mücksch F, Müller R, Schultz C, Müller B, Kräusslich H-G, Briggs JAG. Maturation of the matrix and viral membrane of HIV-1, Science. 373 (2021) 700–4. https://doi.org/10.1126/science.abe6821 .

Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A. 1991;88:3195–9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC51412/ . accessed September 10, 2023.

doi: 10.1073/pnas.88.8.3195 pubmed: 2014240 pmcid: 51412

Bharat TAM, Castillo Menendez LR, Hagen WJH, Lux V, Igonet S, Schorb M, Schur FKM, Kräusslich H-G, Briggs JAG. Cryo-electron microscopy of tubular arrays of HIV-1 gag resolves structures essential for immature virus assembly. Proc Natl Acad Sci U S A. 2014;111:8233–8. https://doi.org/10.1073/pnas.1401455111 .

doi: 10.1073/pnas.1401455111 pubmed: 24843179 pmcid: 4050629

Mattei S, Glass B, Hagen WJH, Kräusslich H-G, Briggs JAG. The structure and flexibility of conical HIV-1 capsids determined within intact virions. Science. 2016;354:1434–7. https://doi.org/10.1126/science.aah4972 .

doi: 10.1126/science.aah4972 pubmed: 27980210

Mendonça L, Sun D, Ning J, Liu J, Kotecha A, Olek M, Frosio T, Fu X, Himes BA, Kleinpeter AB, Freed EO, Zhou J, Aiken C, Zhang P. CryoET structures of immature HIV Gag reveal six-helix bundle. Commun Biol. 2021;4:481. https://doi.org/10.1038/s42003-021-01999-1 .

doi: 10.1038/s42003-021-01999-1 pubmed: 33863979 pmcid: 8052356

Fossen T, Wray V, Bruns K, Rachmat J, Henklein P, Tessmer U, Maczurek A, Klinger P, Schubert U. Solution structure of the human immunodeficiency virus type 1 p6 Protein*. J Biol Chem. 2005;280:42515–27. https://doi.org/10.1074/jbc.M507375200 .

doi: 10.1074/jbc.M507375200 pubmed: 16234236

Solbak SMØ, Reksten TR, Hahn F, Wray V, Henklein P, Henklein P, Halskau Ø, Schubert U, Fossen T. HIV-1 p6 - a structured to flexible multifunctional membrane-interacting protein. Biochim Biophys Acta. 2013;1828:816–23. https://doi.org/10.1016/j.bbamem.2012.11.010 .

doi: 10.1016/j.bbamem.2012.11.010 pubmed: 23174350

Wollert T, Hurley JH. Molecular mechanism of Multivesicular Body Biogenesis by ESCRT complexes. Nature. 2010;464:864–9. https://doi.org/10.1038/nature08849 .

doi: 10.1038/nature08849 pubmed: 20305637 pmcid: 2851844

Jouvenet N, Zhadina M, Bieniasz PD, Simon SM. Dynamics of ESCRT protein recruitment during retroviral assembly. Nat Cell Biol. 2011;13:394–401. https://doi.org/10.1038/ncb2207 .

doi: 10.1038/ncb2207 pubmed: 21394083 pmcid: 3245320

Votteler J, Sundquist WI. Virus budding and the ESCRT pathway. Cell Host Microbe. 2013;14:232–41. https://doi.org/10.1016/j.chom.2013.08.012 .

doi: 10.1016/j.chom.2013.08.012 pubmed: 24034610

Strack B, Calistri A, Craig S, Popova E, Göttlinger HG. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell. 2003;114:689–99. https://doi.org/10.1016/s0092-8674(03)00653-6 .

doi: 10.1016/s0092-8674(03)00653-6 pubmed: 14505569

Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Côté M, Rich RL, Myszka DG, Sundquist WI. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 2001;107:55–65. https://doi.org/10.1016/s0092-8674(01)00506-2 .

doi: 10.1016/s0092-8674(01)00506-2 pubmed: 11595185

Friedrich M, Setz C, Hahn F, Matthaei A, Fraedrich K, Rauch P, Henklein P, Traxdorf M, Fossen T, Schubert U. Glutamic acid residues in HIV-1 p6 regulate virus budding and Membrane Association of Gag. Viruses. 2016;8:117. https://doi.org/10.3390/v8040117 .

doi: 10.3390/v8040117 pubmed: 27120610 pmcid: 4848609

VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(gag). Proc Natl Acad Sci U S A. 2001;98:7724–9. https://doi.org/10.1073/pnas.131059198 .

doi: 10.1073/pnas.131059198 pubmed: 11427703 pmcid: 35409

Morita E, Sandrin V, McCullough J, Katsuyama A, Hamilton IB, Sundquist WI. ESCRT-III protein requirements for HIV-1 budding. Cell Host Microbe. 2011;9:235–42. https://doi.org/10.1016/j.chom.2011.02.004 .

doi: 10.1016/j.chom.2011.02.004 pubmed: 21396898 pmcid: 3070458

de Rocquigny H, Petitjean P, Tanchou V, Decimo D, Drouot L, Delaunay T, Darlix J-L, Roques BP. The Zinc fingers of HIV Nucleocapsid Protein NCp7 Direct Interactions with the viral Regulatory protein Vpr*. J Biol Chem. 1997;272:30753–9. https://doi.org/10.1074/jbc.272.49.30753 .

doi: 10.1074/jbc.272.49.30753 pubmed: 9388214

Kondo E, Göttlinger HG. A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 vpr. J Virol. 1996;70:159–64. https://doi.org/10.1128/JVI.70.1.159-164.1996 .

doi: 10.1128/JVI.70.1.159-164.1996 pubmed: 8523520 pmcid: 189800

Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L. A leucine triplet repeat sequence (LXX)4 in p6gag is important for vpr incorporation into human immunodeficiency virus type 1 particles. J Virol. 1995;69:6873–9. https://doi.org/10.1128/JVI.69.11.6873-6879.1995 .

doi: 10.1128/JVI.69.11.6873-6879.1995 pubmed: 7474102 pmcid: 189602

Zhu H, Jian H, Zhao L-J. Identification of the 15FRFG domain in HIV-1 gag p6 essential for vpr packaging into the virion. Retrovirology. 2004;1:26. https://doi.org/10.1186/1742-4690-1-26 .

doi: 10.1186/1742-4690-1-26 pubmed: 15363109 pmcid: 521086

Kondo E, Mammano F, Cohen EA, Göttlinger HG. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol. 1995;69:2759–64. https://doi.org/10.1128/JVI.69.5.2759-2764.1995 .

doi: 10.1128/JVI.69.5.2759-2764.1995 pubmed: 7707498 pmcid: 188969

Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem. 1999;274:9083–91. https://doi.org/10.1074/jbc.274.13.9083 .

doi: 10.1074/jbc.274.13.9083 pubmed: 10085158

Wanaguru M, Bishop KN. HIV-1 gag recruits oligomeric Vpr via two binding sites in p6, but both mature p6 and vpr are rapidly lost upon target cell entry. J Virol. 2021;JVI0055421. https://doi.org/10.1128/JVI.00554-21 .

Fritz JV, Dujardin D, Godet J, Didier P, De Mey J, Darlix J-L, Mély Y, de Rocquigny H. HIV-1 Vpr oligomerization but not that of Gag directs the Interaction between Vpr and Gag. J Virol. 2010;84:1585–96. https://doi.org/10.1128/jvi.01691-09 .

doi: 10.1128/jvi.01691-09 pubmed: 19923179

Morellet N, Bouaziz S, Petitjean P, Roques BP. NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol. 2003;327:215–27. https://doi.org/10.1016/s0022-2836(03)00060-3 .

doi: 10.1016/s0022-2836(03)00060-3 pubmed: 12614620

Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U. Structural characterization of the HIV-1 vpr N terminus: evidence of cis/trans-proline isomerism. J Biol Chem. 2003;278:43188–201. https://doi.org/10.1074/jbc.M305413200 .

doi: 10.1074/jbc.M305413200 pubmed: 12881523

Chougui G, Munir-Matloob S, Matkovic R, Martin MM, Morel M, Lahouassa H, Leduc M, Ramirez BC, Etienne L, Margottin-Goguet F. HIV-2/SIV viral protein X counteracts HUSH repressor complex. Nat Microbiol. 2018;3:891–7. https://doi.org/10.1038/s41564-018-0179-6 .

doi: 10.1038/s41564-018-0179-6 pubmed: 29891865

Laguette N, Brégnard C, Hue P, Basbous J, Yatim A, Larroque M, Kirchhoff F, Constantinou A, Sobhian B, Benkirane M. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell. 2014;156:134–45. https://doi.org/10.1016/j.cell.2013.12.011 .

doi: 10.1016/j.cell.2013.12.011 pubmed: 24412650

Lv L, Wang Q, Xu Y, Tsao L-C, Nakagawa T, Guo H, Su L, Xiong Y. Vpr targets TET2 for degradation by CRL4VprBP E3 ligase to sustain IL-6 expression and enhance HIV-1 replication. Mol Cell. 2018;70:961–970e5. https://doi.org/10.1016/j.molcel.2018.05.007 .

doi: 10.1016/j.molcel.2018.05.007 pubmed: 29883611 pmcid: 6071318

Yurkovetskiy L, Guney MH, Kim K, Goh SL, McCauley S, Dauphin A, Diehl WE, Luban J. Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex. Nat Microbiol. 2018;3:1354–61. https://doi.org/10.1038/s41564-018-0256-x .

doi: 10.1038/s41564-018-0256-x pubmed: 30297740 pmcid: 6258279

Zhao L, Wang S, Xu M, He Y, Zhang X, Xiong Y, Sun H, Ding H, Geng W, Shang H, Liang G. Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages. Nat Commun. 2021;12:3691. https://doi.org/10.1038/s41467-021-24087-8 .

doi: 10.1038/s41467-021-24087-8 pubmed: 34140527 pmcid: 8211709

Müller B, Patschinsky T, Kräusslich H-G. The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol. 2002;76:1015–24. https://doi.org/10.1128/jvi.76.3.1015-1024.2002 .

doi: 10.1128/jvi.76.3.1015-1024.2002 pubmed: 11773377 pmcid: 135845

Votteler J, Neumann L, Hahn S, Hahn F, Rauch P, Schmidt K, Studtrucker N, Solbak SMØ, Fossen T, Henklein P, Ott DE, Holland G, Bannert N, Schubert U. Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assembly. Retrovirology. 2011;8:11. https://doi.org/10.1186/1742-4690-8-11 .

doi: 10.1186/1742-4690-8-11 pubmed: 21324168 pmcid: 3049138

Salgado GF, Vogel A, Marquant R, Feller SE, Bouaziz S, Alves ID. The role of membranes in the organization of HIV-1 gag p6 and vpr: p6 shows high affinity for membrane bilayers which substantially increases the interaction between p6 and vpr. J Med Chem. 2009;52:7157–62. https://doi.org/10.1021/jm901106t .

doi: 10.1021/jm901106t pubmed: 19883084

Hahn S, Setz C, Wild J, Schubert U. The PTAP sequence within the p6 domain of human immunodeficiency virus type 1 gag regulates its ubiquitination and MHC class I antigen presentation. J Immunol. 2011;186:5706–18. https://doi.org/10.4049/jimmunol.1003764 .

doi: 10.4049/jimmunol.1003764 pubmed: 21482733

Gurer C, Berthoux L, Luban J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol. 2005;79:910–7. https://doi.org/10.1128/JVI.79.2.910-917.2005 .

doi: 10.1128/JVI.79.2.910-917.2005 pubmed: 15613319 pmcid: 538558

Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus. J Virol. 1998;72:2962–8. https://doi.org/10.1128/JVI.72.4.2962-2968.1998 .

doi: 10.1128/JVI.72.4.2962-2968.1998 pubmed: 9525617 pmcid: 109742

Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43:16–29. https://doi.org/10.1016/j.tips.2021.10.004 .

doi: 10.1016/j.tips.2021.10.004 pubmed: 34742581

Demirov DG, Ono A, Orenstein JM, Freed EO. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A. 2002;99:955–60. https://doi.org/10.1073/pnas.032511899 .

doi: 10.1073/pnas.032511899 pubmed: 11805336 pmcid: 117412

Tavassoli A, Lu Q, Gam J, Pan H, Benkovic SJ, Cohen SN. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem Biol. 2008;3:757–64. https://doi.org/10.1021/cb800193n .

doi: 10.1021/cb800193n pubmed: 19053244

Lennard KR, Gardner RM, Doigneaux C, Castillo F, Tavassoli A. Development of a cyclic peptide inhibitor of the p6/UEV protein–protein Interaction. ACS Chem Biol. 2019;14:1874–8. https://doi.org/10.1021/acschembio.9b00627 .

doi: 10.1021/acschembio.9b00627 pubmed: 31411851

Liu F, Stephen AG, Adamson CS, Gousset K, Aman MJ, Freed EO, Fisher RJ, Burke TR. Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists. Org Lett. 2006;8:5165–8. https://doi.org/10.1021/ol0622211 .

doi: 10.1021/ol0622211 pubmed: 17048869 pmcid: 2547129

Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, Daniel MD, Desrosiers RC. Progression to AIDS in the absence of a gene for vpr or vpx. J Virol. 1995;69:2378–83. https://doi.org/10.1128/JVI.69.4.2378-2383.1995 .

doi: 10.1128/JVI.69.4.2378-2383.1995 pubmed: 7884883 pmcid: 188910

Yang X, Lennard KR, He C, Walker MC, Ball AT, Doigneaux C, Tavassoli A, van der Donk WA. A lanthipeptide library used to identify a protein–protein interaction inhibitor. Nat Chem Biol. 2018;14:375–80. https://doi.org/10.1038/s41589-018-0008-5 .

doi: 10.1038/s41589-018-0008-5 pubmed: 29507389 pmcid: 5866752

Strickland M, Ehrlich LS, Watanabe S, Khan M, Strub M-P, Luan C-H, Powell MD, Leis J, Tjandra N, Carter CA. Tsg101 chaperone function revealed by HIV-1 assembly inhibitors. Nat Commun. 2017;8:1391. https://doi.org/10.1038/s41467-017-01426-2 .

doi: 10.1038/s41467-017-01426-2 pubmed: 29123089 pmcid: 5680296

Munshi UM, Kim J, Nagashima K, Hurley JH, Freed EO. An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem. 2007;282:3847–55. https://doi.org/10.1074/jbc.M607489200 .

doi: 10.1074/jbc.M607489200 pubmed: 17158451